MIMRYLO (Rusfertide Acetate) Patent Expiration, LOE Window & CMS Spending

MIMRYLO (Rusfertide Acetate) by Takeda: FDA Orange Book core substance LOE 2034-03-17, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $4,231 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN220605 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-03-17
Last Listed Patent or Exclusivity Date2034-03-17
Orange Book Patents (*PED Extensions)30 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($4,231 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.